Home › Colorectal Cancer › Connecticut › New Haven
Colorectal Cancer clinical trials in New Haven, CT
20 studies for Colorectal Cancer are looking for participants at sites in and around New Haven (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
RecruitingPhase 3
- Yale University School of Medicine /ID# 279373, New Haven
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RecruitingPhase 1/2
- Yale Cancer Center, New Haven
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RecruitingPhase 1
- Exelixis Clinical Site #62, New Haven
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RecruitingPhase 1/2
- Yale University School of Medicine, New Haven
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
RecruitingPhase 1
- Yale Cancer Center, New Haven
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
RecruitingPhase 2
- Yale New Haven Hospital /ID# 270565, New Haven
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
RecruitingPhase 3
- Yale University School Of Medicine, New Haven
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
RecruitingPhase 1/2
- Yale-New Haven Hospital-Yale Cancer Center, New Haven
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RecruitingPhase 1
- Yale Cancer Center, New Haven
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
RecruitingPhase 1/2
- Yale University School of Medicine - Yale Cancer Center, New Haven
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
RecruitingPhase 1
- Yale Cancer Center, New Haven
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
RecruitingPhase 3
- Clinical Study Site, New Haven
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
RecruitingPhase 2
- Yale University, New Haven
FOG-001 in Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 1/2
- Yale University School of Medicine, New Haven
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
RecruitingPhase 1/2
- Yale University, New Haven
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RecruitingPhase 1/2
- Yale Comprehensive Cancer Center, New Haven
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
RecruitingPhase 1/2
- Yale University, New Haven
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
RecruitingPhase 1
- Smilow Cancer Hospital (Yale University), New Haven
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
RecruitingPhase 1
- Yale University, New Haven
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
RecruitingPhase 1/2
- Yale University, Yale Cancer Center, New Haven
About Colorectal Cancer
Colorectal cancer starts in the colon or rectum. It may not cause symptoms at first. Screening tests can help find it early, when treatment is most effective.
More about Colorectal Cancer on MedlinePlus
Colorectal Cancer trials in other cities
- Houston, TX102 studies
- New York City, NY78 studies
- Nashville, TN69 studies
- Boston, MA63 studies
- Los Angeles, CA59 studies
- Arlington, VA52 studies
- St. Louis, MO50 studies
- San Antonio, TX46 studies
- Philadelphia, PA44 studies
- Grand Rapids, MI40 studies
- Baldwin Park, CA37 studies
- Chicago, IL34 studies
Other studies in New Haven
- Non-Small Cell Lung Cancer41 studies
- Breast Cancer38 studies
- Cancer (all types)33 studies
- Metastatic Cancer23 studies
- Lung Cancer22 studies
- Head and Neck Squamous Cell Carcinoma22 studies
- Ovarian Cancer21 studies
- Prostate Cancer20 studies
- Acute Myeloid Leukemia17 studies
- Alcohol Use Disorder (AUD)17 studies
- Opioid Overdose17 studies
- Pancreatic Cancer16 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.